Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

761. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Full Text available with Trip Pro

N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures.To determine whether plasma levels of amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular events or death independent of other (...) available prognostic tests.Prospective cohort study (2000-2002) of 987 individuals in California with stable coronary heart disease in the Heart and Soul Study, who were followed up for a mean of 3.7 (range, 0.1-5.3) years.The association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure). Traditional clinical risk factors, echocardiographic measures, ischemia, other biomarkers, and New York Heart Association classification were adjusted

2007 JAMA

762. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease

and pediatric cardiovascular disease remains controversial, and the practice varies widely even among cardiovascular centers of excellence. A need for EMB exists because speci?c myocardial disorders that have unique prognoses and treatment are seldom diagnosedbynoninvasivetesting. 1 Informedclinicaldecision making that weighs the risks of EMB against the incremental diagnostic,prognostic,andtherapeuticvalueoftheprocedure is especially challenging for nonspecialists because the rel (...) The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease AHA/ACCF/ESC scienti?c statement The role of endomyocardial biopsy in the management of cardiovascular disease A Scienti?c Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Leslie T. Cooper, MD, FAHA, FACC; Kenneth L. Baughman

2007 European Society of Cardiology

763. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Full Text available with Trip Pro

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. The timing of initiation of hormone therapy may influence its effect on cardiovascular disease.To explore whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began.Secondary analysis of the Women's Health Initiative (WHI) randomized controlled trials of hormone therapy in which 10,739 postmenopausal women who had undergone a hysterectomy (...) were randomized to conjugated equine estrogens (CEE) or placebo and 16,608 postmenopausal women who had not had a hysterectomy were randomized to CEE plus medroxyprogesterone acetate (CEE + MPA) or placebo. Women aged 50 to 79 years were recruited to the study from 40 US clinical centers between September 1993 and October 1998.Statistical test for trend of the effect of hormone therapy on coronary heart disease (CHD) and stroke across categories of age and years since menopause in the combined

2007 JAMA Controlled trial quality: predicted high

764. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Full Text available with Trip Pro

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS).To determine the efficacy and safety of ranolazine during long-term treatment of patients with non-ST-elevation ACS.A randomized, double-blind, placebo-controlled, multinational (...) clinical trial of 6560 patients within 48 hours of ischemic symptoms who were treated with ranolazine (initiated intravenously and followed by oral ranolazine extended-release 1000 mg twice daily, n = 3279) or matching placebo (n = 3281), and followed up for a median of 348 days in the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 trial between October 8, 2004, and February 14, 2007.The primary efficacy end point was a composite

2007 JAMA Controlled trial quality: predicted high

765. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. (Abstract)

treatment was effective in Japanese patients with cardiovascular disease.We initiated a multicentre, prospective, randomised controlled trial of 3081 Japanese patients, aged 20-79 years, (mean 65 [SD 10] years) who were undergoing conventional treatment for hypertension, coronary heart disease, heart failure, or a combination of these disorders. In addition to conventional treatment, patients were assigned either to valsartan (40-160 mg per day) or to other treatment without angiotensin receptor (...) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Drugs that inhibit the renin-angiotensin-aldosterone system benefit patients at risk for or with existing cardiovascular disease. However, evidence for this effect in Asian populations is scarce. We aimed to investigate whether addition of an angiotensin receptor blocker, valsartan, to conventional cardiovascular

2007 Lancet Controlled trial quality: predicted high

766. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. Full Text available with Trip Pro

Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical-mediated oxidative stress.To test the hypothesis that reducing body iron stores through phlebotomy will influence clinical outcomes in a cohort of patients with symptomatic peripheral arterial disease (PAD (...) ).Multicenter, randomized, controlled, single-blinded clinical trial based on the Iron (Fe) and Atherosclerosis Study (FeAST) (VA Cooperative Study #410) and conducted between May 1, 1999, and April 30, 2005, within the Department of Veterans Affairs Cooperative Studies Program and enrolling 1277 patients with symptomatic but stable PAD. Those with conditions likely to cause acute-phase increase of the ferritin level or with a diagnosis of visceral malignancy within the preceding 5 years were excluded

2007 JAMA Controlled trial quality: predicted high

767. Statins in primary prevention of cardiovascular disease - Is used based on real evidence or distorted evidence?

Statins in primary prevention of cardiovascular disease - Is used based on real evidence or distorted evidence? Volumen 15. DTB Navarre. Vol 15, No 1. January - February 2007 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB Navarre. Vol 15, No 1. January - February 2007 DTB Navarre. Vol 15, No 1. January - February 2007 Content tools Share it Statins in primary prevention of cardiovascular disease: Is use based on real evidence (...) or distorted evidence? Over the last few years the statins has become the highest consumption therapeutic group within the Navarre Regional Health Service as well as in the rest of Spain. The increasing media impact on the population at large and on the medical profession has created an impression of illness where there is simply a risk factor. The Spanish epidemiology reality differs notably from the circumstances of actual clinical testing with statins. Critical appraisal of the different clinical trials

2007 Drug and Therapeutics Bulletin of Navarre (Spain)

768. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review

. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review. Birmingham: University of Birmingham, West Midlands Health Technology Assessment Group. 2007 Original Paper URL Indexing Status Subject indexing assigned by CRD MeSH Acute Coronary Syndrome /drug therapy; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL /drug effects; Coronary Artery (...) The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review The clinical and cost-effectiveness of intensive versus standard lipid lowering

2007 DARE.

769. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials

Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

770. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

dose of clopidogrel followed by 75 mg/day; two studies omitted the loading dose. Across studies, glycoprotein IIb/IIIa antagonists were used in between 0 and 39% of patients, fibrinolytics used in between 0 and 100%, and heparin used in between 0 and 80%. Participants included in the review Studies in patients with cardiovascular disease were eligible for inclusion. Although most patients in the included studies had an unstable coronary syndrome, some studies were in patients with ST-elevation (...) Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Helton T J, Bavry A A, Kumbhani D J, Duggal S, Roukoz H, Bhatt D L CRD summary The authors

2007 DARE.

771. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases

of orlistat in obese type 2 diabetic patients. Diabetes Care 2002;25:303-8. Van den Hout WB, de Jong Z, Munneke M, et al. Cost-utility and cost-effectiveness of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. Arthritis Rheum 2005;53:39-47. Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Belgium /epidemiology; Cardiovascular Diseases /economics /epidemiology /prevention & Cost of Illness; Cost-Benefit (...) Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Annemans L, Lamotte M, Clarys P, Van den Abeele E Record Status

2007 NHS Economic Evaluation Database.

772. An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis

An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis Article Text Therapeutics An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You

2007 Evidence-Based Medicine

773. Aspirin for the primary prevention of cardiovascular disease in women Full Text available with Trip Pro

Aspirin for the primary prevention of cardiovascular disease in women Aspirin for the primary prevention of cardiovascular disease in women Aspirin for the primary prevention of cardiovascular disease in women Pignone M, Earnshaw S, Pletcher M J, Tice J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The study examined low-dose aspirin (100 mg every other day) for the primary prevention of cardiovascular disease in women. The comparator was no aspirin. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of women at "moderate risk" of cardiovascular disease. Specifically, 65-year-old women with the following risk factor profile

2007 NHS Economic Evaluation Database.

774. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

775. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

776. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of low-dose aspirin (100 mg/day) as primary prevention in patients at increased risk of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical

2007 NHS Economic Evaluation Database.

777. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. Full Text available with Trip Pro

Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. Green tea polyphenols have been extensively studied as cardiovascular disease and cancer chemopreventive agents in vitro and in animal studies. However, the effects of green tea consumption in humans remain unclear.To investigate the associations between green tea consumption and all-cause and cause-specific mortality.The Ohsaki National Health Insurance Cohort Study (...) , a population-based, prospective cohort study initiated in 1994 among 40,530 Japanese adults aged 40 to 79 years without history of stroke, coronary heart disease, or cancer at baseline. Participants were followed up for up to 11 years (1995-2005) for all-cause mortality and for up to 7 years (1995-2001) for cause-specific mortality.Mortality due to cardiovascular disease, cancer, and all causes.Over 11 years of follow-up (follow-up rate, 86.1%), 4209 participants died, and over 7 years of follow-up (follow

2006 JAMA

778. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. (Abstract)

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Cystatin C is an alternative measure of kidney function that may have prognostic importance among elderly persons who do not meet standard criteria for chronic kidney disease (estimated glomerular filtration rate [GFR] > or =60 mL/min per 1.73 m2).To evaluate cystatin C as a prognostic biomarker for death, cardiovascular disease, and incident chronic kidney disease among elderly (...) persons without chronic kidney disease.Cohort study.The Cardiovascular Health Study, a population-based cohort recruited from 4 communities in the United States.4663 elderly persons.Measures of kidney function were creatinine-based estimated GFR by using the Modification of Diet in Renal Disease equation and cystatin C concentration. Outcomes were death, cardiovascular death, noncardiovascular death, heart failure, stroke, myocardial infarction, and incident chronic kidney disease during follow-up

2006 Annals of Internal Medicine

779. Endogenous sex hormones and cardiovascular disease incidence in men. (Abstract)

Endogenous sex hormones and cardiovascular disease incidence in men. Data suggest that endogenous sex hormones (testosterone, dehydroepiandrosterone sulfate [DHEA-S], and estradiol) influence cardiovascular disease (CVD) risk factors and vascular function. Yet, prospective studies relating sex hormones to CVD incidence in men have yielded inconsistent results.To examine the association of circulating sex hormone levels and CVD risk in men.Prospective cohort study.Community-based study (...) in Framingham, Massachusetts.2084 middle-aged white men without CVD at baseline.The authors used multivariable Cox regression to relate baseline levels of testosterone, DHEA-S, and estradiol to the incidence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10 years of follow-up.During follow-up, 386 men (18.5%) experienced a first CVD event. After adjustment for baseline standard CVD risk factors, higher estradiol level was associated with lower risk for CVD (hazard

2006 Annals of Internal Medicine

780. Migraine and risk of cardiovascular disease in women. Full Text available with Trip Pro

Migraine and risk of cardiovascular disease in women. Migraine with aura has been associated with an adverse cardiovascular risk profile and prothrombotic factors that, along with migraine-specific physiology, may increase the risk of vascular events. Although migraine with aura has been associated with increased risk of ischemic stroke, an association with cardiovascular disease (CVD) and, specifically, coronary events remains unclear.To evaluate the association between migraine

2006 JAMA